Authors/Disclosures
|
Roger L. Albin, MD
(University of Michigan)
|
Dr. Albin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Albin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Albin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Albin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaccinex. The institution of Dr. Albin has received research support from NIH-NINDS. The institution of Dr. Albin has received research support from Parkinson's Foundation. The institution of Dr. Albin has received research support from Michael J. Fox Foundation. Dr. Albin has received personal compensation in the range of $5,000-$9,999 for serving as a Grant Application Reivewer with Michael J. Fox Foundation. |
|
Martijn Muller, PhD
(Critical Path Institute)
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Kirk A. Frey, MD, PhD
(Univ of Michigan/Univ Hosp BIG 412 0028)
|
No disclosure on file |
|
Nicolaas I. Bohnen, MD, PhD, FAAN
(University of Michigan)
|
Dr. Bohnen has stock in Delta. The institution of Dr. Bohnen has received research support from NIH. The institution of Dr. Bohnen has received research support from VA. Dr. Bohnen has received research support from NIH. The institution of Dr. Bohnen has received research support from Parkinson fnd. |
|
|
No disclosure on file |